Results · Apr-Jun 2026
Krebs Biochemicals & Industries Q1 FY27 results
Sales grew 27% to ₹7 crore from ₹5.5 crore in Apr-Jun 2025.
Operating profit was ₹0.83 crore, an operating margin of 11.8% (up 49.9 points from a year ago).
The net loss narrowed to ₹2.5 crore from ₹5.3 crore.
Against Jan-Mar 2026: sales +3%, loss widens.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 7.0 | 5.5 | +27% |
| Operating profit (EBITDA) | 0.8 | -2.1 | n/m |
| Operating margin | 11.8% | −38.1% | +49.9 pts |
| Net profit | -2.5 | -5.3 | loss narrows |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.